๐๐๐๐๐๐ ๐๐๐๐๐ข๐ฏ๐๐ฌ ๐๐ ๐๐๐ซ๐ญ๐ข๐๐ข๐๐๐ญ๐ข๐จ๐ง ๐ ๐จ๐ซ ๐๐๐๐ ๐๐๐๐ฉ๐ญ๐ข๐ฏ๐...
๐ฐ ๐๐ฅ๐๐จ๐ง ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐๐๐๐๐ ๐ญ๐จ ๐๐ง๐ก๐๐ง๐๐ ๐
๐๐ฆ๐ญ๐จ๐ฌ๐๐๐จ๐ง๐ ๐๐๐ฌ๐๐ซ ๐๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐จ๐ซ ๐๐๐ญ๐๐ซ๐๐๐ญ ๐๐ฎ๐ซ๐ ๐๐ซ๐ฒ ๐
๐ค Alcon, a global leader in eye care, has announced its intention to acquire LENSAR, Inc., a medical technology company specializing in advanced laser solutions for cataract treatment. The acquisition encompasses LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamlineยฎ software technology, and legacy laser systems, enhancing Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio. โ
๐ฒUnder the terms of the agreement, Alcon will purchase all outstanding shares of LENSAR for $14.00 per share in cash, totalling approximately $356 million. Additionally, there's a non-tradeable contingent value right offering up to $2.75 per share, contingent upon achieving 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. โ
๐จโโ๏ธ The ALLY system, which received FDA clearance in 2022 and European approval in 2024, is the first platform enabling surgeons to perform the entire FLACS procedure within a single, sterile environment. This acquisition aligns with Alcon's strategy to leverage its global footprint to deliver advanced femtosecond laser technology to more surgeons worldwide, thereby improving efficiency in cataract surgery.
โ
๐ The transaction is expected to close in mid-to-late 2025, pending regulatory approvals and LENSAR stockholder consent.
